Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

ABSORICA LD

ISOTRETINOIN

Standard Dose
32MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Prescription
Summary

Approval overview ABSORICA LD is listed in Drugs@FDA under application 211913 (NDA).

Review priority: N/A Marketing status: Prescription Active ingredient ISOTRETINOIN Form and strength CAPSULE;ORAL - 32MG Sponsor SUN PHARM Submission history Latest submission status date: 2026-02-09 00:00:00.

Structured Monograph

Clinical summary

Approval overview ABSORICA LD is listed in Drugs@FDA under application 211913 (NDA). Review priority: N/A Marketing status: Prescription Active ingredient ISOTRETINOIN Form and strength CAPSULE;ORAL - 32MG Sponsor SUN PHARM Submission history Latest submission status date: 2026-02-09 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: N/A

Interaction Notes

  • No interaction notes stored yet.
ABSORICA LD (ISOTRETINOIN) | Drug Monograph | MedicHelpline